(NYSE:COHR), Q1 REVENUE OF $1.58B, INCREASED 17% Y/Y AND, ON A PRO FORMA BASIS, 19% Y/Y ADJUSTED FOR SALE OF AEROSPACE & DEFENSE BUSINESS Q1 GAAP GROSS MARGIN OF 36.6%, INCREASED 249 bps Y/Y; Q1 NON-GAAP GROSS MARGIN OF 38.7%, INCREASED 200 bps Y/Y Q1 GAAP EPS OF $1.19, IMPROVED $1.23 Y/Y; Q1 NON-GAAP EPS […]
Safehold Inc. (NYSE: SAFE) reported results for the third quarter 2025. https://mma.prnewswire.com/media/2039387/Safehold__Carbon_Logo.jpg SAFE published a presentation detailing these results which can be found on its website, www.safeholdinc.comin the “Investors” section. Highlights from the earnings announcement include: — Q3'25 revenue was $96.2 million — Q3'25 net income attributable to common shareholders was $29.3 million — Q3'25
Federated Hermes, Inc. (NYSE: FHI), a global leader in active investing, today announced investment management changes that are expected to take place in 2026. The moves include the retirements of five portfolio managers and the related transitions of portfolio managers and team leaders who will step into new roles as part of the firm's long-term
Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme” or the “Company”), today announced that it intends to offer, subject to market conditions and other factors, $650 million aggregate principal amount of convertible senior notes due 2031 (the “2031 Notes”) and $650 million aggregate principal amount of convertible senior notes due 2032 (the “2032 Notes” and, together with
TrueCar, Inc., (NASDAQ:TRUE) (the “Company,” “we,” “our,” “us,” or “TrueCar”) today announced financial results for the third quarter ended September 30, 2025. https://mma.prnewswire.com/media/75148/truecar_logo.jpg Selected Third Quarter 2025 Financial Highlights — Total revenue of $43.2 million, down from $47.0 million in the second quarter of 2025 and down from $46.5 million in the third quarter of
Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 – Expanded development of dabogratinib into low-grade upper tract urothelial carcinoma (LG-UTUC); IND cleared with U.S. FDA – Cash, cash equivalents, and marketable securities of $274.9 million at Q3 2025; runway through at least 2027 – Tyra Biosciences,
Total revenue of $700 million; excluding COVID-19 and Donor Screening, revenue grew mid-single digits, demonstrating solid underlying growth and momentum — Successful completion of debt refinancing, enhancing financial flexibility through improved terms and reduced amortization obligations — Full-year 2025 revenue and adjusted EBITDA guidance ranges narrowed; adjusted diluted EPS updated to reflect debt refinancing —
Remitly to Host Investor Day on December 9, 2025 GlobeNewswire November 05, 2025 SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) — Remitly Global, Inc. (NASDAQ: RELY) (“Remitly”), a trusted provider of digital financial services that transcend borders, today announced that it will host its first Investor Day since IPO on Tuesday, December 9, 2025 beginning at
Coherent Corp. Reports First Quarter Fiscal 2026 Results GlobeNewswire November 05, 2025 Q1 REVENUE OF $1.58B, INCREASED 17% Y/Y AND, ON A PRO FORMA BASIS, 19% Y/Y ADJUSTED FOR SALE OF AEROSPACE & DEFENSE BUSINESS Q1 GAAP GROSS MARGIN OF 36.6%, INCREASED 249 bps Y/Y; Q1 NON-GAAP GROSS MARGIN OF 38.7%, INCREASED 200 bps Y/Y
Grand Canyon Education, Inc. (NASDAQ: LOPE), (“GCE” or the “Company”), is a publicly traded education services company that currently provides services to 20 university partners. GCE provides a full array of support services in the post-secondary education sector and has developed significant technological solutions, infrastructure and operational processes to provide superior services in these areas